The stock of Mainz Biomed N.V. (MYNZ) has gone down by -4.00% for the week, with a -27.27% drop in the past month and a -21.48% drop in the past quarter. The volatility ratio for the week is 10.74%, and the volatility levels for the past 30 days are 10.25% for MYNZ. The simple moving average for the last 20 days is -17.88% for MYNZ’s stock, with a simple moving average of -60.91% for the last 200 days.
Is It Worth Investing in Mainz Biomed N.V. (NASDAQ: MYNZ) Right Now?
Company’s 36-month beta value is 0.26.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MYNZ is 15.70M, and currently, short sellers hold a 1.92% ratio of that floaft. The average trading volume of MYNZ on May 09, 2024 was 109.87K shares.
MYNZ) stock’s latest price update
Mainz Biomed N.V. (NASDAQ: MYNZ)’s stock price has dropped by -8.19 in relation to previous closing price of 0.78. Nevertheless, the company has seen a loss of -4.00% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-07 that BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
Analysts’ Opinion of MYNZ
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MYNZ reach a price target of $25. The rating they have provided for MYNZ stocks is “Buy” according to the report published on June 21st, 2022.
MYNZ Trading at -24.74% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.00% of loss for the given period.
Volatility was left at 10.25%, however, over the last 30 days, the volatility rate increased by 10.74%, as shares sank -31.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.07% lower at present.
During the last 5 trading sessions, MYNZ fell by -4.00%, which changed the moving average for the period of 200-days by -83.67% in comparison to the 20-day moving average, which settled at $0.8602. In addition, Mainz Biomed N.V. saw -37.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -29.75 for the present operating margin
- 0.57 for the gross margin
The net margin for Mainz Biomed N.V. stands at -29.45. The total capital return value is set at -4.32.
Based on Mainz Biomed N.V. (MYNZ), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -2.96. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -363.2.
Currently, EBITDA for the company is -24.67 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 17.99. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
In a nutshell, Mainz Biomed N.V. (MYNZ) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
